Tandem Investment Advisors’s Novartis NVS Stock Holding History

Tandem Investment Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,596	Closed	-$244K	–	80
2026 Q1	$244K	Buy	+1,596	New	+$245K	0.01%	74

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Tandem Investment Advisors's NVS Position: Q2 2026 in Review

Tandem Investment Advisors sold out of Novartis (NVS) in Q2 2026, closing a stake of 1,596 shares — an estimated $244K sold.

Tandem Investment Advisors first reported a position in NVS in Q1 2026 and held it in 1 quarter. The position peaked at $244K in Q1 2026. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Tandem Investment Advisors reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
Tandem Investment Advisors sold 1,596 Novartis shares in Q2 2026, an estimated $244K.
Tandem Investment Advisors first reported a position in Novartis in Q1 2026 and held it in 1 quarter.
Tandem Investment Advisors's Novartis position peaked at $244K in Q1 2026.
1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Tandem Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.